Taisho Pharmaceutical Holdings Co., Ltd.
4581
Hisse Senetlerindeki Sıralama
#3723
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Hisse Fiyatı
$54.31
Son senkronizasyon: 2024-04-08
Piyasa Değeri
$4.45B
Değişim (1 gün)
-4.14%
Değişim (1 yıl)
0.00%
Ülke
JP
Ticaret Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Kategori
Healthcare
Taisho Pharmaceutical Holdings Co., Ltd. (4581) için tedavüldeki hisse sayısı
October 2026 itibarıyla tedavüldeki hisse sayısı: 0
Taisho Pharmaceutical Holdings Co., Ltd. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 0'dir. October 2026 sonunda şirketin 0 tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Taisho Pharmaceutical Holdings Co., Ltd. (4581) için 2006 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2023 | 81.98M | 0.66% |
| 2022 | 81.44M | 2.04% |
| 2021 | 79.82M | 0.00% |
| 2020 | 79.82M | 0.00% |
| 2019 | 79.82M | -0.09% |
| 2018 | 79.89M | -0.02% |
| 2017 | 79.91M | -1.24% |
| 2016 | 80.91M | -0.19% |
| 2015 | 81.07M | -0.02% |
| 2014 | 81.09M | 0.21% |
| 2013 | 80.92M | -1.60% |
| 2012 | 82.23M | -1.88% |
| 2011 | 83.81M | -2.54% |
| 2010 | 85.99M | -2.41% |
| 2009 | 88.12M | -1.32% |
| 2008 | 89.29M | -2.51% |
| 2007 | 91.60M | -0.95% |
| 2006 | 92.47M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
